Form 13-F position report

CORBUS PHARMACEUTICALS HLDG

Reported by WELLS FARGO & COMPANY MN

CRBP CUSIP 21833P103 Manager CIK 0000072971

Reported 0 shares, down 342,084 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q1 2023
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 27 Through Q1 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 158000
2022-03-31 142000
2022-06-30 88000
2022-09-30 56000
2022-12-31 37800
2023-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

6 quarters
Quarterly reported position history for CORBUS PHARMACEUTICALS HLDG held by WELLS FARGO & COMPANY MN.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2023 Reduced 0 -342,084 (-100.0%) 0 $0 2023-05-12
Q4 2022 Added 342,084 +1,973 (0.6%) < 0.01% $37,800 2023-02-13
Q3 2022 Reduced 340,111 -6,795 (-2.0%) < 0.01% $56,000 2022-11-14
Q2 2022 Added 346,906 +79,083 (29.5%) < 0.01% $88,000 2022-08-12
Q1 2022 Added 267,823 +9,703 (3.8%) < 0.01% $142,000 2022-05-16
Q4 2021 Added 258,120 +7,825 (3.1%) < 0.01% $158,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

63 managers reported CORBUS PHARMACEUTICALS HLDG for Q1 2023.

Managers reporting CORBUS PHARMACEUTICALS HLDG in Q1 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
IFP Advisors Inc Added 100 +86 < 0.01% $595 5 qtrs
MORGAN STANLEY Reduced 0 -83,430 0 $0 32 qtrs
Aries Wealth Management Reduced 0 -15,400 0 $0 22 qtrs
JPMorgan Chase & Co Reduced 0 -43,415 0 $0 22 qtrs
Accel Wealth Management Reduced 0 -1,383 0 $0 4 qtrs
MASSMUTUAL TRUST CO FSB ADV Reduced 0 -500 0 $0 3 qtrs
CHARLES SCHWAB INVESTMENT MANAGEMENT INC Reduced 0 -99,416 0 $0 24 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 0 -986,072 0 $0 31 qtrs
Neuberger Berman Group LLC Reduced 0 -20,000 0 $0 5 qtrs
Kestra Advisory Services LLC Reduced 0 -16,800 0 $0 11 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2023
Filed
May 12, 2023
Filing type
13F-HR
Position type
COM

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.